Pin your most used calculators here by clicking the star in the dropdown.
R-ISS (Multiple Myeloma)
Clinical Context & Background
The Revised International Staging System (R-ISS) combines the original ISS (Albumin, Beta-2 Microglobulin) with chromosomal abnormalities (CA) and lactate dehydrogenase (LDH) to better stratify prognosis in newly diagnosed multiple myeloma. Note: The newer R2-ISS (2022) further incorporates 1q gain/amplification.
Formula Logic
Combines ISS Stage + LDH + CA Genetics (del17p, t(4;14), t(14;16))Reference Data
| R-ISS Stage | Criteria | 5-Year OS |
|---|---|---|
| Stage I | ISS I + Normal LDH + Standard Risk CA | 82% |
| Stage II | Neither Stage I nor Stage III | 62% |
| Stage III | ISS III + (High LDH or High Risk CA) | 40% |
Evidence-based oncology decision support. Verify with clinical guidelines.